{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T20:02:08Z","timestamp":1760385728610,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T00:00:00Z","timestamp":1566518400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T00:00:00Z","timestamp":1566518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12879-019-4389-1","type":"journal-article","created":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T13:02:49Z","timestamp":1566565369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Trend of HIV transmitted drug resistance before and after implementation of HAART regimen restriction in the treatment of HIV-1 infected patients in southern Taiwan"],"prefix":"10.1186","volume":"19","author":[{"given":"Ya-Wei","family":"Weng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I-Tzu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5441-4386","authenticated-orcid":false,"given":"Hung-Chin","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuan-Sheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Ting","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Len","family":"Sy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jui-Kuang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan Shin-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-Shen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,23]]},"reference":[{"key":"4389_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.7326\/0003-4819-151-2-200907210-00003","volume":"151","author":"FJ Palella Jr","year":"2009","unstructured":"Palella FJ Jr, Armon C, Buchacz K, Cole SR, Chmiel JS, Novak RM, et al. The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study. Ann Intern Med. 2009;151:73\u201384.","journal-title":"Ann Intern Med"},{"key":"4389_CR2","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1086\/528802","volume":"197","author":"DR Kuritzkes","year":"2008","unstructured":"Kuritzkes DR, Lalama CM, Ribaudo HJ, Marcial M, Meyer WA 3rd, Shikuma C, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts Virologic failure of an Efavirenz-based regimen in treatment-naive HIV-1\u2013infected subjects. J Infect Dis. 2008;197:867\u201370. \n                    https:\/\/doi.org\/10.1086\/528802\n                    \n                  .","journal-title":"J Infect Dis"},{"key":"4389_CR3","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S1473-3099(11)70032-9","volume":"11","author":"L Wittkop","year":"2011","unstructured":"Wittkop L, Gunthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011;11:363\u201371. \n                    https:\/\/doi.org\/10.1016\/S1473-3099(11)70032-9\n                    \n                  .","journal-title":"Lancet Infect Dis"},{"issue":"18","key":"4389_CR4","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1097\/QAD.0000000000000494","volume":"28","author":"QD Pham","year":"2014","unstructured":"Pham QD, Wilson DP, Law MG, Kelleher AD, et al. Global burden of transmitted HIV drug resistance and HIV-exposure categories: a systematic review and meta-analysis. AIDS. 2014;28(18):2751\u201362. \n                    https:\/\/doi.org\/10.1097\/QAD.0000000000000494\n                    \n                  .","journal-title":"AIDS."},{"issue":"1","key":"4389_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3851\/IMP2437","volume":"18","author":"KM Stadeli","year":"2013","unstructured":"Stadeli KM, Richman DD. Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther. 2013;18(1):115\u201323. \n                    https:\/\/doi.org\/10.3851\/IMP2437\n                    \n                  .","journal-title":"Antivir Ther"},{"issue":"3","key":"4389_CR6","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1086\/427212","volume":"40","author":"RM Novak","year":"2005","unstructured":"Novak RM, Chen L, MacArthur RD, Baxter JD, et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis. 2005;40(3):468\u201374. \n                    https:\/\/doi.org\/10.1086\/427212\n                    \n                  .","journal-title":"Clin Infect Dis"},{"issue":"9849","key":"4389_CR7","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/S0140-6736(12)61038-1","volume":"380","author":"RK Gupta","year":"2012","unstructured":"Gupta RK, Jordan MR, Sultan BJ, Hill A, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet. 2012 Oct 6;380(9849):1250\u20138. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(12)61038-1\n                    \n                  .","journal-title":"Lancet."},{"issue":"1","key":"4389_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/infdis\/jiv012","volume":"212","author":"WL Yang","year":"2015","unstructured":"Yang WL, Kouyos R, Scherrer AU, B\u00f6ni J, et al. Assessing the paradox between transmitted and acquired HIV type 1 drug resistance mutations in the Swiss HIV cohort study from 1998 to 2012. J Infect Dis. 2015;212(1):28\u201338. \n                    https:\/\/doi.org\/10.1093\/infdis\/jiv012\n                    \n                  .","journal-title":"J Infect Dis"},{"issue":"1","key":"4389_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1093\/cid\/cir728","volume":"54","author":"V von Wyl","year":"2012","unstructured":"von Wyl V, Yerly S, B\u00f6ni J, Shah C, et al. Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations. Clin Infect Dis. 2012;54(1):131\u201340. \n                    https:\/\/doi.org\/10.1093\/cid\/cir728\n                    \n                  .","journal-title":"Clin Infect Dis"},{"issue":"5","key":"4389_CR10","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1086\/590943","volume":"47","author":"R Gupta","year":"2008","unstructured":"Gupta R, Hill A, Sawyer AW, Pillay D. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis. 2008;47(5):712\u201322. \n                    https:\/\/doi.org\/10.1086\/590943\n                    \n                  .","journal-title":"Clin Infect Dis"},{"issue":"9839","key":"4389_CR11","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0140-6736(12)60821-6","volume":"380","author":"C Beyrer","year":"2012","unstructured":"Beyrer C, Baral SD, van Griensven F, Goodreau SM, et al. Global epidemiology of HIV infection in men who have sex with men. Lancet. 2012;380(9839):367\u201377. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(12)60821-6\n                    \n                  .","journal-title":"Lancet."},{"key":"4389_CR12","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1093\/jac\/dkr601","volume":"67","author":"C-C Lai","year":"2012","unstructured":"Lai C-C, Hung C-C, Chen M-Y, Sun H-Y, et al. Trends of transmitted drug resistance of HIV-1 and its impact on treatment response to first-line antiretroviral therapy in Taiwan. J Antimicrob Chemother. 2012;67:1254\u201360. \n                    https:\/\/doi.org\/10.1093\/jac\/dkr601\n                    \n                  .","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"4389_CR13","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/jac\/dkv284","volume":"71","author":"C-C Lai","year":"2016","unstructured":"Lai C-C, Liu W-C, Fang C-T, Yang J-Y, et al. Transmitted drug resistance of HIV-1 strains among individuals attending voluntary counselling and testing in Taiwan. J Antimicrob Chemother. 2016;71(1):226\u201334. \n                    https:\/\/doi.org\/10.1093\/jac\/dkv284\n                    \n                  .","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"4389_CR14","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jmii.2014.08.002","volume":"49","author":"YW Weng","year":"2016","unstructured":"Weng YW, Tsai HC, Lee SS, Wu KS, et al. Prevalence and associated factors for HIV-1 transmitted drug resistance in voluntary clients for counseling and testing in southern Taiwan. J Microbiol Immunol Infect. 2016;49(4):487\u201393. \n                    https:\/\/doi.org\/10.1016\/j.jmii.2014.08.002\n                    \n                  .","journal-title":"J Microbiol Immunol Infect"},{"issue":"6","key":"4389_CR15","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1128\/JCM.42.6.2711-2717.2004","volume":"42","author":"SH Eshleman","year":"2004","unstructured":"Eshleman SH, Hackett J Jr, Swanson P, Cunningham SP, et al. Performance of the Celera diagnostics ViroSeq HIV-1 genotyping system for sequence-based analysis of diverse human immunodeficiency virus type 1 strains. J Clin Microbiol. 2004;42(6):2711\u20137. \n                    https:\/\/doi.org\/10.1128\/JCM.42.6.2711-2717.2004\n                    \n                  .","journal-title":"J Clin Microbiol"},{"issue":"6","key":"4389_CR16","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/j.1469-0691.2010.03375.x","volume":"17","author":"C F","year":"2011","unstructured":"F C, Barda B, Ceresola E, Spagnuolo V, et al. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption. Clin Microbiol Infect. 2011;17(6):928\u201334. \n                    https:\/\/doi.org\/10.1111\/j.1469-0691.2010.03375.x\n                    \n                  .","journal-title":"Clin Microbiol Infect"},{"key":"4389_CR17","unstructured":"Stanford University HIV Drug Resistance Database, Available from \n                    https:\/\/hivdb.stanford.edu\n                    \n                  , Version 7.0, released on 2014 Feb 27."},{"issue":"6","key":"4389_CR18","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa1105243","volume":"365","author":"MS Cohen","year":"2011","unstructured":"Cohen MS, Chen YQ, McCauley M, Gamble T, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493\u2013505. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1105243\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"4389_CR19","doi-asserted-by":"publisher","unstructured":"Anglemyer A, Rutherford GW, Horvath T, Baggaley RC, et al. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev. 2013;(4):CD009153. \n                    https:\/\/doi.org\/10.1002\/14651858.CD009153.pub3\n                    \n                  .","DOI":"10.1002\/14651858.CD009153.pub3"},{"issue":"9","key":"4389_CR20","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1056\/NEJMoa1600693","volume":"375","author":"MS Cohen","year":"2016","unstructured":"Cohen MS, Chen YQ, McCauley M, Gamble T, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016;375(9):830\u20139. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1600693\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"9","key":"4389_CR21","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1007\/s10461-018-2124-3","volume":"22","author":"JD L\u00f3pez","year":"2018","unstructured":"L\u00f3pez JD, Shacham E, Brown T. The impact of the Ryan White HIV\/AIDS medical case management program on HIV clinical outcomes: a longitudinal study. AIDS Behav. 2018;22(9):3091\u20139. \n                    https:\/\/doi.org\/10.1007\/s10461-018-2124-3\n                    \n                  .","journal-title":"AIDS Behav"},{"issue":"12","key":"4389_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208919","volume":"13","author":"D MacKellar","year":"2018","unstructured":"MacKellar D, Maruyama H, Rwabiyago OE, Steiner C, et al. Implementing the package of CDC and WHO recommended linkage services: methods, outcomes, and costs of the Bukoba Tanzania combination prevention evaluation peer-delivered, linkage case management program, 2014-2017. PLoS One. 2018;13(12):e0208919. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0208919\n                    \n                  .","journal-title":"PLoS One"},{"issue":"1","key":"4389_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3851\/IMP2780","volume":"20","author":"JD Stekler","year":"2015","unstructured":"Stekler JD, McKernan J, Milne R, Tapia KA, et al. Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007\u20132013. Antivir Ther. 2015;20(1):77\u201380. \n                    https:\/\/doi.org\/10.3851\/IMP2780\n                    \n                  .","journal-title":"Antivir Ther"},{"issue":"11","key":"4389_CR24","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1093\/jac\/dkt238","volume":"68","author":"D Descamps","year":"2013","unstructured":"Descamps D, Assoumou L, Chaix ML, Chaillon A, et al. National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001\u20132011. J Antimicrob Chemother. 2013;68(11):2626\u201331. \n                    https:\/\/doi.org\/10.1093\/jac\/dkt238\n                    \n                  .","journal-title":"J Antimicrob Chemother"},{"key":"4389_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1310\/hct1401-10","volume":"14","author":"C Guti\u00e9rrez","year":"2013","unstructured":"Guti\u00e9rrez C, Hern\u00e1ndez-Novoa B, P\u00e9rez-El\u00edas MJ, Moreno AM, et al. Prevalence of primary resistance mutations to integrase inhibitors in treatment-naive and -experienced patients infected with B and non-B HIV-1 variants. HIV Clin Trials. 2013;14:10\u20136. \n                    https:\/\/doi.org\/10.1310\/hct1401-10\n                    \n                  .","journal-title":"HIV Clin Trials."},{"key":"4389_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/srep35779","volume":"6","author":"SY Chang","year":"2016","unstructured":"Chang SY, Lin PH, Cheng CL, Chen MY, et al. Prevalence of integrase Strand transfer inhibitors (INSTI) resistance mutations in Taiwan. Sci Rep. 2016;6:35779. \n                    https:\/\/doi.org\/10.1038\/srep35779\n                    \n                  .","journal-title":"Sci Rep"},{"issue":"3","key":"4389_CR27","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/hiv.12414","volume":"18","author":"A Tostevin","year":"2017","unstructured":"Tostevin A, White E, Dunn D, Croxford S, et al. Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom. HIV Med. 2017;18(3):204\u201313. \n                    https:\/\/doi.org\/10.1111\/hiv.12414\n                    \n                  .","journal-title":"HIV Med"},{"issue":"5","key":"4389_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125699","volume":"10","author":"Y Vega","year":"2015","unstructured":"Vega Y, Delgado E, Fern\u00e1ndez-Garc\u00eda A, Cuevas MT, et al. Epidemiological surveillance of HIV-1 transmitted drug resistance in Spain in 2004-2012: relevance of transmission clusters in the propagation of resistance mutations. PLoS One. 2015;10(5):e0125699. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0125699\n                    \n                  .","journal-title":"PLoS One"},{"issue":"1","key":"4389_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1310\/hct0801-1","volume":"8","author":"L Ross","year":"2007","unstructured":"Ross L, Lim ML, Liao Q, Wine B, et al. Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-na\u00efve HIV-infected individuals from 40 United States cities. HIV Clin Trials. 2007;8(1):1\u20138. \n                    https:\/\/doi.org\/10.1310\/hct0801-1\n                    \n                  .","journal-title":"HIV Clin Trials"},{"issue":"6","key":"4389_CR30","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1089\/AID.2014.0368","volume":"31","author":"BS Chin","year":"2015","unstructured":"Chin BS, Shin HS, Kim G, Wagner GA, et al. Short communication: increase of HIV-1 K103N transmitted drug resistance and its association with Efavirenz use in South Korea. AIDS Res Hum Retrovir. 2015;31(6):603\u20137. \n                    https:\/\/doi.org\/10.1089\/AID.2014.0368\n                    \n                  .","journal-title":"AIDS Res Hum Retrovir"},{"key":"4389_CR31","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1186\/1471-2334-14-407","volume":"14","author":"D Frentz","year":"2014","unstructured":"Frentz D, Van de Vijver DA, Abecasis AB, Albert J, et al. Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. BMC Infect Dis. 2014;14:407. \n                    https:\/\/doi.org\/10.1186\/1471-2334-14-407\n                    \n                  .","journal-title":"BMC Infect Dis"},{"issue":"7","key":"4389_CR32","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/jac\/dkr157","volume":"66","author":"M Pingen","year":"2011","unstructured":"Pingen M, Nijhuis M, de Bruijn JA, Boucher CA, et al. Evolutionary pathways of transmitted drug-resistant HIV-1. J Antimicrob Chemother. 2011;66(7):1467\u201380. \n                    https:\/\/doi.org\/10.1093\/jac\/dkr157\n                    \n                  .","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"4389_CR33","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1128\/JVI.78.2.603-611.2004","volume":"78","author":"JA Collins","year":"2004","unstructured":"Collins JA, Thompson MG, Paintsil E, Ricketts M, et al. Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants. J Virol. 2004;78(2):603\u201311.","journal-title":"J Virol"},{"key":"4389_CR34","volume-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach, 2nd ed","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. (2016). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach, 2nd ed."},{"issue":"6","key":"4389_CR35","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/01.aids.0000163930.68907.37","volume":"19","author":"PR Harrigan","year":"2005","unstructured":"Harrigan PR, Mo T, Wynhoven B, Hirsch J, et al. Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors. AIDS. 2005;19(6):549\u201354.","journal-title":"AIDS."},{"issue":"14","key":"4389_CR36","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1097\/QAD.0b013e3283636179","volume":"27","author":"NE Mackie","year":"2013","unstructured":"Mackie NE, Dunn DT, Dolling D, Garvey L, et al. The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults. AIDS. 2013;27(14):2245\u201353. \n                    https:\/\/doi.org\/10.1097\/QAD.0b013e3283636179\n                    \n                  .","journal-title":"AIDS."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4389-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-4389-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4389-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T23:06:49Z","timestamp":1598051209000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-4389-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,23]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4389"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-4389-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2019,8,23]]},"assertion":[{"value":"29 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The present study was approved by the Institutional Review Board of Kaohsiung Veterans General Hospital KVGH; (approval nos. VGHKS97-CT3\u201314, VGHKS98-CT1\u201308 and VGHKS15-CT5\u201310) and all patients provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare taht they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"741"}}